The company uses a proprietary platform called ACCESS to discover new antibiotics that combat emerging diseases and antibiotic resistance. They offer a suite of antibiotic compounds that target areas of unmet medical need. Demuris uses innovative assays to screen for inhibitors that act differently from existing antibiotics and provides medicinal chemistry expertise to make initial inhibitors more drug-like. They aim to build a strong intellectual property portfolio for out-licensing to pharmaceutical and biotechnology companies.